## BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyteassociated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of t
โฆ LIBER โฆ
Nivolumab plus Ipilimumab in Advanced Melanoma
โ Scribed by Wolchok, Jedd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Rizvi, Naiyer A.; Lesokhin, Alexander M.; Segal, Neil H.; Ariyan, Charlotte E.; Gordon, Ruth-Ann; Reed, Kathleen; Burke, Matthew M.; Caldwell, Anne; Kronenberg, Stephanie A.; Agunwamba, Blessing U.; Zhang, Xiaoling; Lowy, Israel; Inzunza, Hector David; Feely, William; Horak, Christine E.; Hong, Quan; Korman, Alan J.; Wigginton, Jon M.; Gupta, Ashok; Sznol, Mario
- Book ID
- 120548999
- Publisher
- Massachusetts Medical Society
- Year
- 2013
- Tongue
- English
- Weight
- 646 KB
- Volume
- 369
- Category
- Article
- ISSN
- 0096-6762
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Nivolumab plus Ipilimumab in Advanced Me
โ
Wolchok, Jedd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Ri
๐
Article
๐
2013
๐
Massachusetts Medical Society
๐
English
โ 646 KB
Nivolumab and ipilimumab therapy for adv
โ
Burki, Talha Khan
๐
Article
๐
2013
๐
The Lancet
๐
English
โ 206 KB
Ipilimumab extends survival in advanced
๐
Article
๐
2008
๐
Adis International Limited (now part of Wolters Kl
โ 139 KB
Ipilimumab for advanced metastatic melan
โ
Starz, Hans
๐
Article
๐
2012
๐
Informa plc
๐
English
โ 152 KB
Ipilimumab plus Dacarbazine for Previous
โ
Robert, Caroline; Thomas, Luc; Bondarenko, Igor; O'Day, Steven; Weber, Jeffrey;
๐
Article
๐
2011
๐
Massachusetts Medical Society
๐
English
โ 659 KB
Ipilimumab in melanoma
โ
Specenier, Pol
๐
Article
๐
2012
๐
Expert Reviews
๐
English
โ 949 KB